Is mild fatigue a normal post‑procedural symptom after left atrial appendage closure with a Watchman device?

Is Mild Fatigue Normal After Watchman Placement?

Mild fatigue in the first few weeks after Watchman device placement can occur and should prompt evaluation to rule out serious complications, though it is not specifically documented as an expected post-procedural symptom in the major guidelines or clinical trials.

Understanding Post-Procedural Symptoms

The available evidence does not identify fatigue as a typical or "normal" post-procedural symptom following left atrial appendage closure with the Watchman device. However, context matters significantly here:

What the Guidelines Tell Us About Post-Procedural Complications

The 2012 ESC Guidelines 1 and the PROTECT AF trial data show that serious peri-procedural complications primarily include:

• Pericardial effusion/tamponade (occurring in approximately 4.8% of cases)
• Major bleeding requiring transfusion
• Procedure-related stroke (1.1%)
• Device embolization (0.6%)

Importantly, one guideline specifically mentions that "undue fatigue" in the early postoperative period may represent postpericardiotomy syndrome with tamponade 2. This is a critical red flag that requires immediate evaluation with echocardiography.

Clinical Context and Timing

If fatigue occurs within the first few weeks post-procedure:

• Urgent evaluation is warranted to exclude:

  • Pericardial effusion/tamponade (can occur up to several weeks after the procedure) 2
  • Device-related complications
  • Bleeding complications
  • Anemia from procedural blood loss or anticoagulation

• Key warning signs that should prompt immediate assessment 2:

  • Fever
  • Chest pain
  • Abdominal pain
  • Vomiting
  • Syncope or near-syncope

Post-Procedural Medication Effects

The standard post-Watchman antithrombotic regimen may contribute to fatigue:

• Initial 45 days: Oral anticoagulation (warfarin or DOAC) 1
• Months 1-6: Dual antiplatelet therapy (aspirin + clopidogrel)
• Long-term: Aspirin alone

Real-world data from the EWOLUTION registry 3 shows varied antithrombotic strategies, with DAPT used in 60% initially. These medications, particularly when combined, can cause:

• Bleeding (even minor, subclinical)
• Anemia
• General malaise

Recommended Approach

For any patient reporting fatigue after Watchman placement:

1. Immediate assessment (within 24-48 hours):

   • Complete blood count to assess for anemia
   • Echocardiography to evaluate for pericardial effusion
   • Clinical examination for signs of bleeding or infection

2. Standard follow-up schedule should be maintained 2:

   • 24 hours post-procedure
   • 45 days (with transesophageal echocardiography)
   • 6 months
   • 12 months

3. Device-specific complications to monitor 4, 5:

   • Device-related thrombus (occurs in approximately 4% of cases) 6
   • Peri-device leak
   • Device migration or erosion

Clinical Bottom Line

Do not dismiss fatigue as "normal" without proper evaluation. While some degree of post-procedural recovery is expected with any cardiac intervention, fatigue is not a documented typical symptom in the Watchman literature and may signal complications that require urgent intervention. The high success rate (98.5%) and relatively low complication rate 5 of the procedure should not lead to complacency when patients report new symptoms.

The safest approach is to evaluate promptly rather than reassure prematurely, given that serious complications like pericardial effusion can present with subtle symptoms including fatigue and can occur weeks after the procedure 2.